Preclinical evaluation and automated synthesis of [89Zr]ZrDFOSquaramide-girentuximab for diagnostic imaging of carbonic anhydrase IX positive tumours

Autor: Asif Noor, Emily R. McGowan, Jessica K. Van Zuylekom, Carleen Cullinane, Peter D. Roselt, Rodney J. Hicks, Michael P. Wheatcroft, Paul S. Donnelly

Publikováno v: EJNMMI Radiopharmacy and Chemistry, Vol 9, Iss 1, Pp 1-13 (2024)

Abstract Background Carbonic Anhydrase IX (CAIX) is a zinc metalloenzyme that is over-expressed in many cancers making it a valid target for targeted diagnostic imaging with Positron Emission Tomography (PET). The monoclonal antibody girentuximab bin

Externí odkaz: https://doaj.org/article/f79af442f61f43abaf2bbd84ee7caa50

Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study

Autor: Akhurst, T, Alipour, R, Au, L, Banks, P, Emerson, B, Hussain, N, Haskali, M, Lewin, J, Linklater, R, Kostos, L, Kashyap, R, Krishanth, P, Kong, G, Kumar, A, Murphy, D, Roselt, P, Sandhu, S, Scalzo, M, Tran, B, Wallace, R, Spain, L, Bourke, H, Milton, A, Russo, D, Bills, M, Chew, C, Hsieh, W, Crouch, B, Smyth, D, Pandelus, S, Lam, H, Gan, C, Goh, J, Scott, A, Hafeez, U, Ackermann, U, Young, K, Poon, A, Pathmaraj, K, Schembri, G, Roach, P, Bailey, D, Hung, T, Asad, A, Hagan, T, Watts, J, Campbell, E, Chua, W, Pal, A, Crumbaker, M, Nguyen, A, Yam, A, Chen, J, Ardolino, L, Kongrak, K, Ratnayake, L, Azad, Arun A ^*, Bressel, Mathias, Tan, Hsiang, Voskoboynik, Mark, Suder, Aneta, Weickhardt, Andrew J, Guminski, Alexander, Francis, Roslyn J, Saghebi, Javad, Dhiantravan, Nattakorn, Joshua, Anthony M, Emmett, Louise, Horvath, Lisa, Murphy, Declan G, Hsiao, Edward, Balakrishnar, Bavanthi, Lin, Peter, Redfern, Andrew, Macdonald, William, Ng, Siobhan, Lee, Sze-Ting, Pattison, David A, Nadebaum, David, Kirkwood, Ian D, Hofman, Michael S

Publikováno v: In The Lancet Oncology October 2024 25(10):1267-1276

ImmunoPET: IMaging of cancer imMUNOtherapy targets with positron Emission Tomography: a phase 0/1 study characterising PD-L1 with 89Zr-durvalumab (MEDI4736) PET/CT in stage III NSCLC patients receiving chemoradiation study protocol

Autor: Christian Wichmann, Sagun Parakh, Gerard G Hanna, Thomas John, Jason Callahan, Benjamin Blyth, Michael MacManus, Daniel Steinfort, Andrew M Scott, Lisa Devereux, Fiona Hegi-Johnson, Stacey E Rudd, Tim Akhurst, Peter Roselt, Jenny Trinh, Paul S Donnelly, Rod Hicks, Stephen Fox, Kate Burbury

Publikováno v: BMJ Open, Vol 12, Iss 11 (2022)

Background ImmunoPET is a multicentre, single arm, phase 0–1 study that aims to establish if 89Zr-durvalumab PET/CT can be used to interrogate the expression of PD-L1 in larger, multicentre clinical trials.Methods The phase 0 study recruited 5 PD-L

Externí odkaz: https://doaj.org/article/3ec7e11a980b4b738c6b1a546c955538

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Effective Preparation of [18F]Flumazenil Using Copper-Mediated Late-Stage Radiofluorination of a Stannyl Precursor

Autor: Mohammad B. Haskali, Peter D. Roselt, Terence J. O’Brien, Craig A. Hutton, Idrish Ali, Lucy Vivash, Bianca Jupp

Publikováno v: Molecules, Vol 27, Iss 18, p 5931 (2022)

(1) Background: [18F]Flumazenil 1 ([18F]FMZ) is an established positron emission tomography (PET) radiotracer for the imaging of the gamma-aminobutyric acid (GABA) receptor subtype, GABAA in the brain. The production of [18F]FMZ 1 for its clinical us

Externí odkaz: https://doaj.org/article/05ab28228a434363be8fe0e251362268